Market Reports

From dark art to an age of enlightenment

From dark art to an age of enlightenment

Much is happening in the realms of Almac’s GMP peptides business in terms of growth, development and strategic operations. And, with the company’s current focus on neoantigen-derived vaccines that harness the body’s own immune system to fight cancer, Dr Kevin Robinson zoomed in to find out more
The application of picodroplet technology for biopharmaceutical discovery and scientific research

The application of picodroplet technology for biopharmaceutical discovery and scientific research

Picodroplet technologies continue to push the boundaries of biologic discovery by accelerating research, expanding the scope of exploration and reducing drug discovery and development costs, explains Olivia Hughes, Senior Marketing Associate at Sphere Fluidics
Plastic pallets and the COVID response

Plastic pallets and the COVID response

Jim Hardisty explores the logistical challenges of distributing the COVID vaccine, how Goplasticpallets.com has been supporting the COVID response and why selecting the right pallet for your application is crucial
Derisking topical formulation development with multifactorial disease models

Derisking topical formulation development with multifactorial disease models

Today’s market for topical pharmaceuticals is valued at around $95 billion, with development efforts focused on small molecules and biologics. Forecast to grow by $70 billion during the next 4–5 years, this is a fast-moving area in which cost-effective development is essential, report Dr Jon Lenn, Chief Technology Officer, and Prof. Marc Brown, Chief Scientific Officer and Cofounder, MedPharm
Traceability: the backbone of the pharmaceutical supply chain

Traceability: the backbone of the pharmaceutical supply chain

The pharmaceutical industry is one in which speed and quality are essential ingredients to a successful business. The proper software ensures suppliers become a force to help, not hinder, these factors, explains Andrew Bray, Managing Director, K3
The increasing power of single-cell omics: changing the future of medicine

The increasing power of single-cell omics: changing the future of medicine

Advances in the single-cell genomic analysis of cells and tissues, including the required computational methods, have now put systematic, high-resolution and comprehensive reference maps of all human cells within our reach. Paradigm4's Marilyn Matz, CEO and cofounder, and Dr Zachary Pitluk, VP of Life Sciences and Healthcare, report
Drug dose delivery development, manufacturing and commercialisation trends: part II

Drug dose delivery development, manufacturing and commercialisation trends: part II

In the wake of patient-centricity in the pharmaceutical industry, drug delivery technologies have emerged as a central driver of therapeutic and patient success. Dr Kevin Robinson went online with Manuel Leal, Business Development Director, Idifarma, Steve Rode, Manager Business Development, Capsules and Health Ingredients, Lonza, and John Ross, President, Mayne Pharma US/Metrics Contract Services, to find out more
Technology to transform the capture and processing of drug safety data

Technology to transform the capture and processing of drug safety data

The ultimate goal of pharmacovigilance is to prevent adverse drug reactions, thus maximising the benefit:risk ratio for as many patients as possible, reports Dr Andrew Rut, CEO and founder, MyMeds&Me
Navigating the sea change of pharmaceutical outsourcing: part II

Navigating the sea change of pharmaceutical outsourcing: part II

After what has oft-been described as an unprecedented period of turbulence in almost every aspect of our everyday lives, Dr Kevin Robinson sat down with experts from a number of pharmaceutical contract development and manufacturing organisations (CDMOs) to discuss how the events of the past year have affected the activity and outlook of the industry’s outsourcing sector
Real-time monitoring of pharmaceutical coatings by optical coherence tomography (OCT)

Real-time monitoring of pharmaceutical coatings by optical coherence tomography (OCT)

The coating process is the last step of tablet production and thus influences some of the critical quality attributes (CQAs) of these oral solid dosage forms. RCPE's Stephan Sacher, Senior scientist, Process and Manufacturing Science, Matthias Wolfgang, Scientist, Process and Manufacturing Science, Anna Peter, Scientist, Process and Manufacturing Science, Sandra Stranzinger, Senior scientist, Advanced Products and Delivery, and Johannes Khinast, CEO and Scientific Director, explain
Moulded glass vials secure COVID-19 vaccine supply

Moulded glass vials secure COVID-19 vaccine supply

Although different materials have been trialled and tested, glass remains the most widely used type of primary container for parenteral drug products, writes Dr Jingwei Zhang, R&D Director, SGD Pharma
Immunotherapy: antibody drug conjugates from a small molecule perspective

Immunotherapy: antibody drug conjugates from a small molecule perspective

Immunotherapies such as ADCs deliver a more targeted treatment against cancer that improves the quality of life for the patient compared with traditional chemotherapies, write Maurits Janssen, Senior Director, Strategic Business Development, and Bernhard Stump, Associate Director, Head of Process Development Bioconjugates, Lonza Pharma & Biotech
API sourcing: what to look for in a supplier

API sourcing: what to look for in a supplier

Jonathan Knight, Director of Market Intelligence and New Technologies at Cambrex, presents an overview of the API sourcing marketplace, summarising the factors that need to be considered when choosing an API supplier in the light of recent global market, political and economic developments
From the lab to the last mile: optimising the pharma cold chain (part I)

From the lab to the last mile: optimising the pharma cold chain (part I)

With more than 40 COVID-19 vaccines in human testing worldwide and an expected 14 billion vaccines needed to facilitate a global vaccination, the stakes are high when it comes to safe storage and distribution. Dr Kevin Robinson recently caught up with Stirling Ultracold’s CEO, Dusty Tenney, and Robin Grimwood, President and COO of Infinity Biologix, to discuss the criticality of ULT storage as we approach a vaccine delivery date
Model-based optimisation of mixed solvent systems for spray drying

Model-based optimisation of mixed solvent systems for spray drying

Spray drying is a common and effective approach to enhance the bioavailability of low-solubility small molecules. As the process requires intimate knowledge of aspects such as droplet trajectories, in this article Jonathan L. Cape, Kimberly B. Shepard and Michael M. Morgen, from Lonza Pharma & Biotech, examine different approaches to spray drying and ways to optimise drug production and quality
Developing innovative antivirals for novel viruses

Developing innovative antivirals for novel viruses

Since the emergence of COVID-19, researchers worldwide have striven to study and overcome this new disease and the novel coronavirus (SARS-CoV-2) that causes it. To achieve this, we will probably need both vaccines and antiviral drugs, report Zamas Lam, Senior Vice President of Preclinical Development, and John Kolman, Vice President of Translational Medicine, QPS

Trending Articles

  1. A rules-based approach to labelling and artwork management: Part I Many organisations today are experiencing unprecedented demands from regulatory authorities and consumers alike for product labelling to be made clearer and more informative, says Graham Francis, Channel Marketing Manager, Kallik
  2. A microfluidic approach to production of alginate beads for cell encapsulation Gurinder Vinner, Material Scientist at Dolomite Microfluidics, discusses the benefits of continuous microfluidic production for the encapsulation of mammalian cells with no loss of viability
  3. Recombinant versus synthetic peptide synthesis: the perks and drawbacks Since the introduction of novel peptide drugs into the market, the demand for polypeptide manufacturing has significantly increased, reports Dr Philipp Markolin
  4. UK pharma shifts as Merck and AstraZeneca scale back: can CDMOs fill the gap? Recent major site withdrawals and investment pauses have raised concerns about the UK’s industrial strength. But CDMOs say agility, innovation and technical expertise could redefine how and where drugs are made
  5. CMC strategies for the acceleration of commercial-ready ADC manufacturing The potential for antibody-drug conjugate (ADC) programmes to accelerate from early to late stage clinical development highlights the need to establish commercial launch-ready manufacturing early and efficiently, reports Courtney Morgret, Senior Scientist, Manufacturing Sciences, AbbVie

Upcoming event

CPhI Milan

6–8 October 2026 | Exhibition | Fiera Milano, Italy See all